Zhejiang Chimin Pharm Co Ltd (603222) — Net Asset Quality Index
Zhejiang Chimin Pharm Co Ltd (603222) has a Net Asset Quality Index of 52.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.27 Billion minus total liabilities of CN¥1.07 Billion yields net assets of CN¥1.20 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Zhejiang Chimin Pharm Co Ltd (603222) asset resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Chimin Pharm Co Ltd Net Asset Quality Index Over Time (2011–2025)
This chart shows how Zhejiang Chimin Pharm Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the index stands at 52.9%, representing net assets of CN¥1.20 Billion against total assets of CN¥2.27 Billion CNY. See working capital to net assets of Zhejiang Chimin Pharm Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Zhejiang Chimin Pharm Co Ltd (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Chimin Pharm Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 603222 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 56.5% | CN¥1.31 Billion | CN¥2.31 Billion | CN¥1.00 Billion | ▼ -8.4 pp |
| 2024 | 65.0% | CN¥1.57 Billion | CN¥2.41 Billion | CN¥846.22 Million | ▼ -2.0 pp |
| 2023 | 66.9% | CN¥1.66 Billion | CN¥2.48 Billion | CN¥820.13 Million | ▲ +1.6 pp |
| 2022 | 65.4% | CN¥1.77 Billion | CN¥2.71 Billion | CN¥939.64 Million | ▲ +8.7 pp |
| 2021 | 56.7% | CN¥1.37 Billion | CN¥2.43 Billion | CN¥1.05 Billion | ▲ +11.0 pp |
| 2020 | 45.6% | CN¥1.05 Billion | CN¥2.29 Billion | CN¥1.25 Billion | ▼ -5.8 pp |
| 2019 | 51.5% | CN¥1.07 Billion | CN¥2.08 Billion | CN¥1.01 Billion | ▲ +2.2 pp |
| 2018 | 49.3% | CN¥1.05 Billion | CN¥2.12 Billion | CN¥1.08 Billion | ▼ -9.7 pp |
| 2017 | 58.9% | CN¥928.28 Million | CN¥1.57 Billion | CN¥646.63 Million | ▼ -28.8 pp |
| 2016 | 87.7% | CN¥808.94 Million | CN¥922.43 Million | CN¥113.49 Million | ▼ -1.3 pp |
| 2015 | 89.0% | CN¥750.99 Million | CN¥844.01 Million | CN¥93.02 Million | ▲ +18.9 pp |
| 2014 | 70.1% | CN¥441.55 Million | CN¥630.04 Million | CN¥188.49 Million | ▲ +1.7 pp |
| 2013 | 68.4% | CN¥488.13 Million | CN¥713.38 Million | CN¥225.24 Million | ▲ +5.8 pp |
| 2012 | 62.6% | CN¥432.53 Million | CN¥690.63 Million | CN¥258.10 Million | ▲ +4.2 pp |
| 2011 | 58.5% | CN¥383.04 Million | CN¥655.30 Million | CN¥272.26 Million | — |